louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01176448: Laser Resurfacing Versus Dermabrasion for Scar Revision
Official title: A Comparison Evaluation of Fractional Laser Therapy and Dermabrasion for Scar Revision
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cicatrix
Dermabrasion
Coagulation, Laser
Keywords: Cicatrix
Dermabrasion
Coagulation, Laser
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2010-08-06
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Dermabrasion has been the historical standard used for resurfacing scars on the skin. Recently, fractionated laser therapy has been FDA approved for scar resurfacing. This study intends to compare dermabrasion versus fractionated laser therapy for scar resurfacing.


Eligibility criteria: Inclusion Criteria:

* Post-surgical or post traumatic scar on face or scalp.
* Age 18 or older
* Able to read and comprehend English
* Willing to follow treatment schedule and post treatment care requirements
* Signed the informed consent form
* Fitzpatrick skin type I-III

Exclusion Criteria:

* known photosensitivity
* Taken any medications known to induce photosensitivity in previous three months
* Taken Accutane within past 12 months
* Pregnant or nursing
* Currently on topical or oral antibiotics
* Immunocompromised status
* Skin type IV or greater

Primary outcomes:
measure: Safey Data Score Based on Ordinal Ratings of Erythema, Edema, Bleeding, Eschar After Resurfacing
timeFrame: Day 0, Week1, Month 1
Secondary outcomes:
measure: Visual Analog Scale for Assessing Scar Improvement.
timeFrame: 3 months
Other outcomes:
Locations:
city: Edina
country: United States
facility: Zel Skin and Laser
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: John J Christophel, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jared Christophel J, Elm C, Endrizzi BT, Hilger PA, Zelickson B. A randomized controlled trial of fractional laser therapy and dermabrasion for scar resurfacing. Dermatol Surg. 2012 Apr;38(4):595-602. doi: 10.1111/j.1524-4725.2011.02283.x. Epub 2012 Jan 23.
Clinical trial NCT02250430: A Phase 1 Study Assessing Local Cutaneous Effects of SB204
Official title: A Phase 1, Single-Center, Split-Face Study Assessing Local Cutaneous Effects After Application of SB204 2% and SB204 4% in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne Vulgaris
Keywords: acne
Lead sponsor: Novan, Inc.
Sponsor class: INDUSTRY
First posted: 2014-09-26
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.

Detailed description: This study is to evaluate local cutaneous effects, including intensity and duration of erythema and changes in pH following 5 applications (twice daily for two days and once daily on the third day) of SB204 2% and SB204 4% twice daily to the face for 3 days.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers

Exclusion Criteria:

* Women who are pregnant or nursing
* Subject with known sensitivity to a component of the test materials

Primary outcomes:
measure: Intensity of erythema following application of SB204 2% and SB204 4%.
timeFrame: 3 days
measure: Duration of erythema following application of SB204 2% and SB204 4%.
timeFrame: 3 days
Secondary outcomes:
measure: pH on the surface of the skin after topical application of 2 concentrations of SB204
timeFrame: 3 days
Other outcomes:
Locations:
city: Broomall
country: United States
facility: KGL
state: Pennsylvania
Study officials:
affiliation: KGL, Inc.
name: Stuart Lessin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05349448: Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study
Official title: Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Pain, Neuropathic
Keywords: neuropathy
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2022-04-27
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: use of dexmedtemodine to augment analgesia in cases of failed back surgery


Eligibility criteria: Inclusion Criteria:

* Age group. 25-75ys old
* Both sex.
* persistent (at least 6 month) pain and or disability following laminectomy with or without sensory-motor neurological deficits or any form of urinary or bowel incontinence
* Patients suffering from persistent (\> 6 months) back pain following laminectomy for spinal canal stenosis and/or discectomy for herniated nucleus pulposus documented by magnetic resonance imaging (MRI) were included for screening and enrollment.

Exclusion Criteria:

* Diabetic patients.
* Refusal to participate
* MRI with disc sequestration, concurrent sacro-ilitis, facet arthropathy .
* Coagulopathic patients

Primary outcomes:
measure: pain assesment
timeFrame: 6 months
Secondary outcomes:
measure: functional diability
timeFrame: 6 months
measure: acute complications
timeFrame: 6 hours after injection
Other outcomes:
Locations:
city: ALMinya
country: Egypt
facility: Minia University
state: Minia
Study officials:
References:
Clinical trial NCT01638130: Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers
Official title: Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Brain Neoplasms, Primary Malignant
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2012-07-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a high-grade glioma and their caregivers

Brief summary: The purpose of this study is to explore the experiences and needs of patients with a high-grade glioma and their caregivers. Semi-structured interviews with patients and caregivers will be conducted and analysed using Grounded-Theory approach.


Eligibility criteria: Inclusion Criteria:

* Adults
* Patients with a primary high-grade glioma who are treated with chemo or were treated with chemo
* Caregivers of patients with a primary high-grade glioma who are treated with chemo or were treated with chemo
* Able to be interviewed
* Dutch

Exclusion Criteria:

* Patients with cerebral metastases
* Patients and caregivers who withdraw their informed consent
* Emotionally and cognitive not being able to be interviewed

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
state: Vlaams-Brabant
Study officials:
References:
Clinical trial NCT01302730: Ankylosing Spondylitis and Spondyloarthritis Evaluation Tool Study
Official title: A Self-Administered Questionnaire for Early Detection of Axial Spondyloarthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ankylosing Spondylitis
Spondylarthritis
Keywords: ankylosing spondylitis
spondylarthritis
inflammatory back pain
seronegative
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: University of California, San Francisco
name: Oregon Health and Science University
name: Cedars-Sinai Medical Center
First posted: 2011-02-24
Enrollment: 490
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients referred to rheumatologist office will be potentially eligible.

Brief summary: This study aims to test whether a new instrument (questionnaire) is useful for identifying patients with ankylosing spondylitis.


Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent

Exclusion Criteria:

* Inability to provide informed consent

Primary outcomes:
measure: Physician diagnosis of Ankylosing Spondylitis
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Eswar Krishnan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01848730: Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
Official title: A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Post-herpetic Neuralgia
Lead sponsor: Convergence Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2013-05-07
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.

Detailed description: A 3 week randomised crossover study to investigate the effect of repeat oral dosing of CNV2197944 75 mg tid versus placebo for on the pain experienced in post-herpetic neuralgia (PHN. Each 3 week treatment period is seperated by a 2 week washout period. The primary outcome measure is the change from baseline in the PI-NRS after three weeks of treatment. Secondary outcome measures include pain responder rates, clinical and patient global impressions of pain, and the Neuropathic Pain Symptom Inventory.

Eligibility criteria: Inclusion Criteria:

Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent.

Patients with post-herpetic neuralgia (PHN) with pain at screening present for more than 3 months after healing of the herpes zoster skin rash. The maximum duration of PHN will be no longer than 5 years.

Exclusion Criteria:

Patients having other severe pain, which may impair the self-assessment of the pain due to PHN.

Patients who have received nerve blocks for neuropathic pain within 4 weeks prior to the start of the single-blind placebo run-in Certain medications used to relieve the pain of PHN, specifically gabapentinoids (gabapentin and pregabalin), carbamazepine and topical agents (eg capsaicin, lidocaine) Patients with a documented failure to respond to a maximally tolerated dose regimen of gabapentin or pregabalin.

Patients taking more than one medication to treat the PHN pain

Primary outcomes:
measure: Pain Intensity Numerical Rating Scale
timeFrame: 21 days
Secondary outcomes:
measure: Pain responder rates
timeFrame: 21 days
measure: Neuropathic Pain Symptom Inventory
timeFrame: 21 days
Other outcomes:
Locations:
city: Cape Town
country: South Africa
facility: Christiaan Barnard Memorial Hospital
Study officials:
affiliation: Christiaan Barnard Memorial Hospital, Cape Town, South Africa
name: Milton Raff, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01549730: Cervix Hypoxia FAZA
Official title: A Feasibility Study of Hypoxia Imaging in Patients With Cervix Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cervix Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2012-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to look for low levels of oxygen (hypoxia) in your cervix cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how cervix cancer grows and responds to treatments like radiotherapy and chemotherapy. Doctors at Princess Margaret Hospital have measured hypoxia in over 300 patients. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix
* TNM (7th edition) cT1-4, N0-1, M0-1
* Intention to treat using radiotherapy with or without concurrent cisplatin chemotherapy according to the current treatment policies of the PMH Gynecology Group
* No cytotoxic anti-cancer therapy for cervix cancer prior to study entry
* A negative urine or serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age
* Ability to provide written informed consent to participate in the study

Exclusion Criteria:

* Prior complete or partial hysterectomy
* Carcinoma of the cervical stump
* Inability to lie supine for more than 30 minutes
* Patients taking the drug disulfuram (Antabuse)

Primary outcomes:
measure: Number of patients treated with the PET tracer FAZA to image primary tumor hypoxia in patients with cervix cancer prior to treatment with radiotherapy and concurrent cisplatin chemotherapy
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Princess Margaret Hospital
state: Ontario
Study officials:
affiliation: Princess Margaret Hospital, University Health Network
name: Michael Milosevic, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03602430: Cholecalciferol on Hemodialysis Patients
Official title: Effect of Cholecalciferol on Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hemodialysis Complication
Vitamin D Deficiency
Vascular Calcification
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital).
* Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.


Eligibility criteria: Inclusion Criteria:

1. Both sexes aged between 18-75 years
2. Patients on HD greater than 3 months at least.
3. Stable clinical condition (no hospitalization in the previous 3 months)
4. Informed consent in accordance with the Declaration of Helsinki.
5. PTH level between 150 - 800 pg/ml.

Exclusion Criteria:

1. Hypersensitivity to cholecalciferol.
2. Participant in an another clinical trial within the past 4 weeks.
3. Judged to be unsuitable as a subject by the attending physician.
4. Pregnant or breastfeeding female

Primary outcomes:
measure: Vitamin D level
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Hospital
Study officials:
References:
citation: Alshahawey M, El Borolossy R, El Wakeel L, Elsaid T, Sabri NA. The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study. Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):626-633. doi: 10.1016/j.numecd.2020.09.014. Epub 2020 Sep 21.
Clinical trial NCT02165930: Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers
Official title: An Open Label, Single Dose, Randomized, Two Way Crossover Study to Estimate Oxycodone Relative Bioavailability in Healthy Volunteers Following Administration of PF 00345439 Formulation K 40 Mg Under Fasting Conditions With 40% Ethanol Compared With Water
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Bioavailability
oxycodone
ethanol interaction
healthy volunteers
Lead sponsor: PainT
Sponsor class: UNKNOWN
First posted: 2014-06-18
Enrollment: 17
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To Estimate Bioavailability Of 40 Mg Doses Of Pf-00345439 Formulation K Under Fasting Conditions with 40% Ethanol Compared with Water in Healthy Volunteers


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* History of moderate alcohol consumption
* Total body weight exceeding 64 kg

Exclusion Criteria:

* Evidence or history of clinically significant disease.
* Positive urine drug test
* History of alcoholism or heavy alcohol consumption

Primary outcomes:
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
Secondary outcomes:
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Concentration at time 24 hours (C24)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Plasma Decay Half-Life (t1/2)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Pfizer Investigational Site
state: Kansas
city: Overland Park
country: United States
facility: Pfizer Investigational Site
state: Kansas
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00904930: Evaluation of the Periotest Method in Dental Traumatology
Official title: Evaluation of the Periotest Method as a Tool for Tooth Mobility Monitoring and Splint Rigidity Assessment in Dental Traumatology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dental Trauma
Keywords: Tooth mobility assessment
Splinting
Splint Rigidity
Lead sponsor: University of Erlangen-Nürnberg Medical School
Sponsor class: OTHER
First posted: 2009-05-20
Sex: ALL
Minimum age (years): 19
Maximum age (years): 36
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Dental students Dental Clinic 1 and 2

Brief summary: Background/Aims: The Periotest® method represents a technique for objective tooth mobility assessment. The aims of this study were: 1. receiving information about normal Periotest® values in vertical and horizontal dimension on periodontally healthy teeth for individuals aged 20-35, 2. investigating the reliability of the Periotest® method in terms of intra-serial and inter-serial reproducibility before splinting and with an applied dental trauma splint, 3. evaluating the splint effect of two different wire-composite splints in vivo.

Materials and Methods: On periodontally healthy dental students (n=33; mean age 24.7 years) Periotest® values were measured on reproducible measuring points, in vertical and horizontal dimension and before splinting and after splint insertion. Three readings were taken per serial to observe the intra-serial reproducibility, and for testing inter-serial reproducibility three serials were measured (Friedman-test; P ≤ 0.001). Two different wire-composite-splints (1 = Dentaflex 0.45 mm, 2 = Strengtheners 0.8x1.8) were inserted, the Periotest® values were measured and the splint effects were calculated and compared (Whitney-Mann-U-test; P ≤ 0.001).


Eligibility criteria: Inclusion Criteria:

* age 19-36
* healthy upper front teeth

Exclusion Criteria:

* periodontal disease
* orthodontic treatment during the investigation period
* history of dental trauma
* fillings or restorations on upper front teeth
* endodontically treated teeth

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Erlangen
country: Germany
facility: Friedrich-Alexander-University Erlangen-Nuremberg
state: Bavaria
Study officials:
References:
Clinical trial NCT05614830: Effectiveness Taif University P. O. Box 11099 Taif 21944 Effectiveness of Dry Needling in Management of Myofacial Trigger Point
Official title: Effectiveness of Dry Needling in Management of Myofacial Trigger Point In Trapezius Muscle
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myofacial Trigger Points
Lead sponsor: Taif University
Sponsor class: OTHER
First posted: 2022-11-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: myofascial pain syndrome is considered to be a chronic condition due to sensitive pressure points within the muscle recognized as trigger points

Generally the aim of this study will be :

* To investigate the effectiveness of dry needling on trigger point in trapezius muscle
* Evaluate the pain level before and after the applications of dry needling on trigger points
* compare between the effects of dry needling and physical therapy exercise program


Eligibility criteria: Inclusion Criteria:

* Clinically active trigger point and expression of symptoms of neck pain in trapezius which had lasted for at least 3 months.
* Having a pain level higher than 4 and lower than 8 on Visual Analogue Scale ( VAS )
* Did not receive any other form of neck treatment during the previous month.

Exclusion Criteria:

* Presence of cardiopulmonary disease , the application process requires the subject to be in prone position to expose the area of treatment, this position is un-preferable for cardiopulmonary patients
* History of neck surgery
* Trigger point treatment in the last 30 days
* Any contraindications for dry needling such as local infection, skin disease ,severe postural disorder , tumor , rheumatoid arthritis, cervical spine stenosis and bilateral upper extremity symptoms
* pregnancy

Primary outcomes:
measure: Pain level
timeFrame: 6 weeks
measure: Neck disability index
timeFrame: 6 weeks
Secondary outcomes:
measure: Depression
timeFrame: 6 weeks
measure: Neck Range of motion
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
References: